(CATX) Perspective Therapeutics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE MKT (USA) | Market Cap: 454m USD | Total Return: 73.3% in 12m

Radiopharmaceuticals, Alpha Therapies, Cancer Drugs, Medical Isotopes
Total Rating 38
Safety 34
Buy Signal -0.10
Medical Devices
Industry Rotation: +5.3
Market Cap: 454M
Avg Turnover: 4.38M
Risk 3d forecast
Volatility95.5%
VaR 5th Pctl15.2%
VaR vs Median-4.30%
Reward TTM
Sharpe Ratio0.96
Rel. Str. IBD77.2
Rel. Str. Peer Group84.8
Character TTM
Beta0.690
Beta Downside0.515
Hurst Exponent0.544
Drawdowns 3y
Max DD90.71%
CAGR/Max DD-0.10
CAGR/Mean DD-0.17
EPS (Earnings per Share) EPS (Earnings per Share) of CATX over the last years for every Quarter: "2021-03": -0.01, "2021-06": -0.01, "2021-09": -0.02, "2021-12": -0.01, "2022-03": -0.01, "2022-06": -0.01, "2022-09": -0.03, "2022-12": -0.02, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.04, "2023-12": -0.09, "2024-03": -0.02, "2024-06": -0.18, "2024-09": -0.21, "2024-12": -0.57, "2025-03": -0.25, "2025-06": -0.29, "2025-09": -0.35, "2025-12": -0.5058, "2026-03": -0.2528,
Last SUE: 1.06
Qual. Beats: 1
Revenue Revenue of CATX over the last years for every Quarter: 2021-03: 2.384, 2021-06: 2.359, 2021-09: 2.6, 2021-12: 2.71, 2022-03: 2.91, 2022-06: 2.505, 2022-09: 1.717, 2022-12: 1.835, 2023-03: 1.83, 2023-06: 1.5, 2023-09: 1.909, 2023-12: 0.337, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.342, 2025-06: 0.29, 2025-09: 0.209, 2025-12: 0.043, 2026-03: 0.076,
Rev. CAGR: -74.71%
Rev. Trend: -93.8%
Last SUE: -0.11
Qual. Beats: 0

Warnings

Share dilution 44.4% YoY

Interest Coverage Ratio -323.8 is critical

Altman Z'' -7.03 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: CATX Perspective Therapeutics

Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company specializing in Targeted Alpha Therapies (TAT) for oncology. The company’s pipeline includes VMT-a-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, both of which are currently in Phase 1/2a clinical trials. Unlike traditional beta-emitting therapies, alpha therapies utilize high-energy particles with a shorter range to minimize damage to surrounding healthy tissue.

The company maintains a clinical collaboration with Bristol Myers Squibb to evaluate combination treatments involving its [212Pb] VMT01 candidate and nivolumab. The radiopharmaceutical sector is characterized by high barriers to entry due to the complex logistics of isotope procurement and specialized manufacturing requirements. Examining ValueRays detailed metrics can provide further clarity on how CATX compares to its industry peers.

Headquartered in Seattle, Perspective Therapeutics transitioned from its former identity as Isoray, Inc. in 2022. Its current development focus extends to PSV359, targeting fibroblast activation protein alpha, and radioligand therapies for metastatic castration-resistant prostate cancer.

Headlines to Watch Out For
  • Phase 1/2a clinical trial data for VMT-a-NET determines radiopharmaceutical market viability
  • Lead-212 isotope supply chain stability impacts manufacturing scale and production costs
  • Strategic collaboration with Bristol Myers Squibb validates targeted alpha therapy platform
  • Regulatory approval timelines for SSTR2-expressing tumor treatments drive long-term valuation
  • Competition from established beta-emitting therapies like Lutathera pressures future market share
Piotroski VR-10 (Strict) 0.0
Net Income: -111.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.26 > 0.02 and ΔFCF/TA 5.37 > 1.0
NWC/Revenue: 39.5k% < 20% (prev 59.4k%; Δ -19.9k% < -1%)
CFO/TA -0.22 > 3% & CFO -92.4m > Net Income -111.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.75 > 1.5 & < 3
Outstanding Shares: last quarter (103.6m) vs 12m ago 43.18% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.17% > 50% (prev 0.10%; Δ 0.06% > 0%)
Interest Coverage Ratio: -323.8 > 6 (EBITDA TTM -110.6m / Interest Expense TTM 353k)
Altman Z'' -7.03
A: 0.59 (Total Current Assets 275.4m - Total Current Liabilities 31.5m) / Total Assets 410.8m
B: -0.88 (Retained Earnings -361.0m / Total Assets 410.8m)
C: -0.31 (EBIT TTM -114.3m / Avg Total Assets 370.1m)
D: -5.70 (Book Value of Equity -361.1m / Total Liabilities 63.3m)
Altman-Z'' = -7.03 = D
Beneish M -3.19
DSRI: 0.41 (Receivables 58.0k/78.0k, Revenue 618k/342k)
GMI: 1.00 (fallback, negative margins)
AQI: 0.64 (AQ_t 0.10 / AQ_t-1 0.15)
SGI: 1.81 (Revenue 618k / 342k)
TATA: -0.05 (NI -111.1m - CFO -92.4m) / TA 410.8m)
Beneish M = -3.19 (Cap -4..+1) = AA
What is the price of CATX shares?

As of May 27, 2026, the stock is trading at USD 4.16 with a total of 1,436,917 shares traded.
Over the past week, the price has changed by +10.64%, over one month by -2.58%, over three months by -17.79% and over the past year by +73.33%.

Is CATX a buy, sell or hold?

Perspective Therapeutics has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CATX.

  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CATX price?
Analysts Target Price 12.9 210.8%
Perspective Therapeutics (CATX) - Fundamental Data Overview as of 24 May 2026
Market Cap USD = 453.9m (453.9m USD * 1.0 USD.USD)
P/E Forward = 25.7069
P/S = 734.4723
P/B = 1.3064
Revenue TTM = 618k USD
EBIT TTM = -114.3m USD
EBITDA TTM = -110.6m USD
Long Term Debt = 1.55m USD (from longTermDebt, last quarter)
Short Term Debt = 1.07m USD (from shortTermDebt, last quarter)
Debt = 2.62m USD (from shortLongTermDebtTotal, last quarter) (leases 2.62m already included)
Net Debt = -268.3m USD (calculated: Debt 2.62m - CCE 270.9m)
Enterprise Value = 185.6m USD (453.9m + Debt 2.62m - CCE 270.9m)
Interest Coverage Ratio = -323.8 (Ebit TTM -114.3m / Interest Expense TTM 353k)
EV/FCF = -1.73x (Enterprise Value 185.6m / FCF TTM -107.3m)
FCF Yield = -57.83% (FCF TTM -107.3m / Enterprise Value 185.6m)
 FCF Margin = -17.4k% (FCF TTM -107.3m / Revenue TTM 618k)
 Net Margin = -18.0k% (Net Income TTM -111.1m / Revenue TTM 618k)
 Gross Margin = unknown ((Revenue TTM 618k - Cost of Revenue TTM 3.65m) / Revenue TTM)
 Tobins Q-Ratio = 0.45 (Enterprise Value 185.6m / Total Assets 410.8m)
Interest Expense / Debt = 13.47% (Interest Expense 353k / Debt 2.62m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.3m (EBIT -114.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 275.4m / Total Current Liabilities 31.5m)
Debt / Equity = 0.01 (Debt 2.62m / totalStockholderEquity, last quarter 347.4m)
 Debt / EBITDA = 2.43 (negative EBITDA) (Net Debt -268.3m / EBITDA -110.6m)
 Debt / FCF = 2.50 (negative FCF - burning cash) (Net Debt -268.3m / FCF TTM -107.3m)
 Total Stockholder Equity = 265.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.03% (Net Income -111.1m / Total Assets 410.8m)
RoE = -17.74% (Net Income TTM -111.1m / Total Stockholder Equity 626.6m)
RoCE = -18.19% (EBIT -114.3m / Capital Employed (Equity 626.6m + L.T.Debt 1.55m))
 RoIC = -82.51% (negative operating profit) (NOPAT -90.3m / Invested Capital 109.4m)
 WACC = 8.42% (E(453.9m)/V(456.5m) * Re(8.41%) + D(2.62m)/V(456.5m) * Rd(13.47%) * (1-Tc(0.21)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.41 | Cagr: 82.09%
 [DCF] Fair Price = unknown (Cash Flow -107.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.06 | # QB: 1
Revenue Correlation: -93.75 | Revenue CAGR: -74.71% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=-3.52% | Revisions=+14% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.30 | Chg30d=-6.46% | Revisions=+33% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.17 | Chg30d=+7.72% | Revisions=+25% | GrowthEPS=+16.7% | GrowthRev=-55.9%
EPS next Year (2027-12-31): EPS=-1.15 | Chg30d=+1.83% | Revisions=+0% | GrowthEPS=+1.5% | GrowthRev=+18.0%
[Analyst] Revisions Ratio: +33%